insulin therapy and other management issues in type 1 diabetes mellitus philip raskin, md jaime a....
TRANSCRIPT
![Page 1: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/1.jpg)
Insulin Therapy and Other Management Issues in Type 1
Diabetes Mellitus
Philip Raskin, MD
Jaime A. Davidson, MD
The University of Texas Southwestern Medical Center
![Page 2: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/2.jpg)
Treatment Guidelines for Diabetes
• American Diabetes Association1
– HbA1c <7.0%– Preprandial BG 70–130 mg/dL– Postprandial BG <180 mg/dL
• American Association of Clinical Endocrinologists2
– HbA1c ≤6.5%– Preprandial BG <110 mg/dL– Postprandial BG <140 mg/dL
• International Diabetes Federation– HbA1c <6.5%3,4
– Preprandial BG <110 mg/dL3,4
– Postprandial BG <160 mg/dL4
1. American Diabetes Association. Diabetes Care. 2012;35(suppl 1):S11-S63. 2. AACE. Endocr Pract. 2011;17(suppl 2):1-53. 3. IDF. Global Guideline for Type 2 Diabetes. 2005. 4. IDF. Guideline for Management of PostMeal Glucose in Diabetes. 2011.
![Page 3: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/3.jpg)
Type 1 Diabetes Mellitus
• Type 1 (immune-mediated beta cell destruction leading to absolute insulin deficiency)
• Dependent on exogenous insulin• Prone to ketoacidosis• Usually lean, but not always• Recent weight loss• Abrupt onset of symptoms, often before
age 30• May occur at any age
![Page 4: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/4.jpg)
Natural History of Type 1 Diabetes
CELLULAR (T CELL) AUTOIMMUNITY
LOSS OF FIRST PHASE INSULIN RESPONSE
(IVGTT)
GLUCOSE INTOLERANCE(OGTT)
HUMORAL AUTOANTIBODIES(ICA, IAA, Anti-GAD65, IA2Ab, etc.)
PUTATIVEENVIRONMENTAL
TRIGGER
CLINICALONSET
TIME
BE
TA C
EL
L M
AS
S
DIABETES
“PRE”-DIABETES
GENETICPREDISPOSITION
INSULITISBETA CELL INJURY
With permission from Skyler JS, et al. Diabetes. 2011;60:1-8.
![Page 5: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/5.jpg)
As Early as Possible in the Course of Diabetes
• Metabolic Memory: Benefits of good diabetes control are long-lasting in both type 1 and type 2 diabetes1,2
• Intensive diabetes control in older diabetic individuals with long-standing Type 2 diabetes and well-established microvascular and macrovascular complications can result in bad outcomes (ACCORD, etc)?3
When to Initiate Intensive Therapy in Type 1 Diabetes?
1. DCCT/EDIC Study Research Group. N Engl J Med. 2005;353:2643-2653.2. UKPDS Group. N Engl J Med. 2008;359:1577-1589.3. ACCORD Study Group. N Engl J Med. 2011;364:818-828.
![Page 6: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/6.jpg)
DCCT Microvascular Complication Event Rates
1. DCCT Research Group. Ophthalmology. 1995;102:647-661. 2. DCCT Research Group. Kidney Int. 1995;47:1703-1720. 3. DCCT Research Group. Ann Intern Med. 1995;122:561-568.
RetinopathyProgression1
LaserRx1
Microalbuminuria2 Albuminuria2 ClinicalNephropathy3
![Page 7: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/7.jpg)
DCCT/EDIC Research Group. JAMA. 2002;287:2563-2569.
Further Retinopathy Progression Over 7 Years of EDIC from the Level
at DCCT Closeout• Even after intensive therapy was stopped at
the end of DCCT, effects of intensive therapy persisted for >7 years
• Difference between conventional and intensive therapy accelerated even after the treatments ended
• After 7 years of EDIC– Risk reduction: 62% with intensive
therapy (95% CI 51%-70%, P <.001)
![Page 8: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/8.jpg)
Meta-analysis: Improved Glucose =Reduction in Macrovascular Events
• With reduction in glucose, there is greater improvement in macrovascular events in glucose T1DM vs T2DM*
Stettler C, et al. Am Heart J. 2006;152:27-38.
Combined incidenceAny macrovascular event T1DM 0.38 (95% CI, 0.26–0.56)T2DM 0.81 (95% CI, 0.73–0.91)
Cardiac eventsT1DM 0.41 (95% CI, 0.19–0.87)T2DM 0.91 (95% CI, 0.80–1.03)
Peripheral vascular eventsT1DM 0.39 (95% CI, 0.25–0.62)T2DM 0.58 (95% CI, 0.38–0.89)
Cerebrovascular eventsT1DM 0.34 (95% CI, 0.05–2.57)T2DM 0.58 (95% CI, 0.4–0.74)
*Incidence rate ratios are shown for T1DM (based on 8 randomized studies) and T2DM (based on 6 randomized studies).
![Page 9: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/9.jpg)
Insulin
![Page 10: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/10.jpg)
Insulin Analog
Insulin produced by technology that uses recombinant DNA to produce an insulin molecule
that is slightly different from human insulin in structure as well as pharmacokinetic/
pharmacodynamic properties
![Page 11: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/11.jpg)
Insulin Preparations
Agents
Regular, NPH
Human 70/30
Insulin aspart, glulisine and lispro, insulin glargine and detemir
Insulin lispro 75/25, 50/50Biphasic insulin aspart 70/30
Class
Human Insulin
Premixed HumanInsulin
Insulin Analogs
Premixed InsulinAnalogs
![Page 12: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/12.jpg)
Time Action Profiles of Insulin Products
• Rapid-acting insulin analogs (insulin aspart, insulin glulisine, insulin lispro)– Duration of action: 4–6 hours
• Regular insulin– Duration of action: 8–10 hours
• NPH insulin– Duration of action: 12–18 hours
• Long-acting insulin analogs (insulin glargine, insulin detemir)– Duration of action: 20–24 hours
![Page 13: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/13.jpg)
Rapid-Acting Analogs vs Regular Human Insulin
Insu
lin
Lev
el (m
U/m
L)
800
700
600
500
400
300
200
100
0
With permission from Woodworth, et al. Diabetes. 1993;42(suppl 1):54A.
0 1 2 3 4 5 6 7 8
Time (hours)
0.05 U/kg (n = 6)
0.1 U/kg (n = 9)
Regular Human Insulin
0.2 U/kg (n = 9)
0.3 U/kg (n = 3)
800
700
600
500
400
300
200
100
0
0 1 2 3 4 5 6 7 8
Time (hours)
Rapid-Acting Analogs
Glu
cose
In
suli
n R
ate
(mg
/min
)
![Page 14: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/14.jpg)
Braak EW, et al. Diabetes Care. 1996;19:1437-1440.
Rapid-Acting Analogues
Tmax (hours)*
Regular Human Insulin
1.0
0.77
1.0
3.8
1.3
3.1
* 0.2 U/kg sc.
Comparison of Insulin Absorption by Injection Site
![Page 15: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/15.jpg)
Management of Type 1 Diabetes
![Page 16: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/16.jpg)
Intensive Diabetes Management
• Goals of Therapy• Tools of Therapy• Systems of Therapy
Defined by
![Page 17: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/17.jpg)
Intensive Diabetes Management
• Near-normal glycemia
• Near-normal glycohemoglobin
• Prevention of complications
• Absence of hypoglycemia
Goals
![Page 18: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/18.jpg)
Intensive Diabetes Management
• Multiple-component insulin regimen• Daily blood glucose monitoring• Careful balance of food intake, activity, and
insulin dosage• An action plan for patient adjustment of the
above, and the use of insulin supplements• Defined target blood glucose levels
(individualized)
Elements of Management
![Page 19: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/19.jpg)
Intensive Diabetes Management
• Frequent contact between patient and health care providers
• Patient education and motivation
• Psychological support
• Assessment (glycohemoglobin)
Elements of Management
![Page 20: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/20.jpg)
Intensive Diabetes Management
• Basal
• Meal-related
Components of Insulin Replacement
![Page 21: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/21.jpg)
Basal Bolus Therapy
![Page 22: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/22.jpg)
Pla
sm
a In
sulin
(U
/mL
)
Time4:00 8:00 12:00 16:00 20:00 24:00 4:00 8:00
Breakfast Lunch Dinner
Glargine/Detemir
75
50
25
0
Basal/Bolus Idealized Absorption of Analog Insulin
Bedtime
Lispro/Aspart/Glulisine
Courtesy of Davidson JA.
![Page 23: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/23.jpg)
Insulin Pumps
![Page 24: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/24.jpg)
Time of Day
20
40
60
80
100 B L D
0600 06000800 18001200 2400
Bolus
Continuous infusion for basal delivery
Bolus
U/m
L
Bolus
Insulin Pump Delivery Rapid-Acting Analogs
B=breakfast; L=lunch; D=dinnerCourtesy of Davidson JA.
![Page 25: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/25.jpg)
Insulin Pumps
![Page 26: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/26.jpg)
Wearing the Insulin Pump
![Page 27: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/27.jpg)
Intensive Diabetes Management
• Basal: 40%–60%
• Premeal: 40%–60%– If according to carbohydrate
0.8–1.2 units/gram carbohydrate– If according to % of total daily dose
15%–25% before breakfast 15% before lunch 15%–20% before dinner
Insulin Dose Distribution
![Page 28: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/28.jpg)
• Insulin dosage
• Insulin timing
• Meal size
• Meal content
Intensive Diabetes Management
Preprandial Algorithms
![Page 29: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/29.jpg)
Intensive Diabetes Management
• Supplements
• Adjustments
Insulin Dose Changes
![Page 30: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/30.jpg)
Intensive Diabetes Management
• Supplements– Compensatory– Anticipatory
Insulin Dose Changes
![Page 31: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/31.jpg)
• Compensatory supplements– Based on prevailing blood glucose– Corrects blood glucose outside “target”
range– Alters basic dose for that point in time
Intensive Diabetes Management
Insulin Dose Changes
![Page 32: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/32.jpg)
Intensive Diabetes Management
• Blood glucose– <50 mg/dL– 51–100 mg/dL– 101–150 mg/dL– 151–200 mg/dL– 201–250 mg/dL– 251–300 mg/dL– >300 mg/dL
• Fast-acting insulin– Decrease 2 units– Decrease 1 unit– Take usual dose– Increase 1 unit– Increase 2 units– Increase 3 units– Increase 4 units
Compensatory Supplements
Per Dr. Raskin.
![Page 33: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/33.jpg)
Intensive Diabetes Management
• What is my blood glucose now?
• Do I plan to eat more or less than usual?
• Will I be more or less active after eating?
• What has happened under these circumstances previously?
Insulin Dose Changes
Mealtime Questions
![Page 34: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/34.jpg)
Insulin Dose Changes
• Adjustments– Based on pattern over several days– ~10% increase or decrease in insulin
component preceding BG measurement– Change one component at a time
Intensive Diabetes Management
![Page 35: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/35.jpg)
Insulin Timing
• Regular insulin usually 30–60 minutes before meals
• Rapid-acting analogs taken at mealtime or better yet 15 minutes before– Increase time interval if blood glucose above
target (further from meal)– Decrease time interval if blood glucose
below target (closer to meal)
Intensive Diabetes Management
![Page 36: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/36.jpg)
Meal Size or Carbohydrate Content
• Decrease if blood glucose above target or less activity planned
• Increase if blood glucose below target or more activity planned
Intensive Diabetes Management
![Page 37: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/37.jpg)
Criteria for Selection of Patients
• Suboptimal glycemic control
• Motivation to pursue intensive therapy
• Willing and able to perform frequent SMBG
• Sufficient education and ability
• Adequate psychological stability
• Appropriate financial resources
• Skilled medical staff available
Intensive Diabetes Management
![Page 38: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/38.jpg)
Contraindications
• Hypoglycemia unawareness
• Counterregulatory unresponsiveness
• Age
• Medical reasons, debilitated, short life expectancy, malignancy, etc
Intensive Diabetes Management
![Page 39: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/39.jpg)
Benefits of Insulin Pump Therapy
• Allows for flexibility in schedule
• More physiologic and reproducible
• Insulin delivery more predictable
• Less hypoglycemia (exercise)
Intensive Diabetes Management
![Page 40: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/40.jpg)
Self-Blood Glucose Monitoring
Essential Component of Intensive Management
Intensive Diabetes Management
![Page 41: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/41.jpg)
Blood Glucose Monitoring
• Initially, check blood glucose before and 1.5–2 hours after each meal and at bedtime
• Weekly at 2:00 AM–3:00 AM
• Four blood glucose checks before each meal after targets are achieved
![Page 42: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/42.jpg)
Effect of Memory Meter on HbA1c in Patients with Type 1 Diabetes
• N = 22 intensively treated T1DM patients (using insulin pump or 4 daily insulin injections)
• Monthly mean HbA1c across 12 months– HbA1c 6.9% ± 0.12% before memory meter– HbA1c 6.4% ± 0.10% while a memory meter was
used– P = .0004– Difference in slopes P = .046
• As the frequency of SMBG (tests/day) increased, HbA1c decreased: r = −0.61, P <.01
Strowig SM, Raskin P. Diabetes Care. 1998;21:1694-1698.
![Page 43: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/43.jpg)
![Page 44: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/44.jpg)
Hypoglycemia
![Page 45: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/45.jpg)
Hypoglycemia
• Identify hypoglycemia patterns and relate to insulin peaks
• Look for causes — Lifestyle issues
Exercise Food Alcohol
— Medical causes Altered kidney or liver function Hormonal deficiencies (eg, pituitary or adrenal) Rapid gastric emptying Hypoglycemia unawareness
National Diabetes Information Clearinghouse (NDIC). Hypoglycemia. Accessed 1/29/13 at: http://diabetes.niddk.nih.gov/dm/pubs/hypoglycemia/#symptoms.
![Page 46: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/46.jpg)
46
15 g CHO as juice, soda, or glucose tablets
![Page 47: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/47.jpg)
47
![Page 48: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/48.jpg)
Monitoring • GLYCOHEMOGLOBIN1
– 1–2 MONTHS DURING STABILIZATION– 2–4 MONTHS ROUTINELY
• BLOOD PRESSURE—every visit1
– Probably should be measured in both supine and standing positions2
• URINE PROTEIN/MICROALBUMIN—annually1,2
• EYE EXAMS—annually1,2
• FOOT EXAMS—annually1,2
• LIPIDS—annually1,2
1. American Diabetes Association. Diabetes Care. 2012;35(suppl 1):S11-S63. 2. AACE. Endocr Pract. 2011;17(suppl 2):1-53.
![Page 49: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/49.jpg)
Adherence
![Page 50: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/50.jpg)
Adherence to Insulin in Pediatric Type 1 Diabetes
• Meta-analysis of 21 studies (N = 2492)• Increased adherence is associated with
decreased HbA1c values– Greater association pre-DCCT vs post-
DCCT, possibly due to increased complexity of regimens
Hood KK, et al. Pediatrics. 2009;124:e1171-e1179.
![Page 51: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/51.jpg)
Adherence During Transition to Adolescence in Type 1 Diabetes
• 2-year longitudinal, multisite study of youth aged
9–11 (N = 225)• HbA1c increased (8.2 to 8.6%, P <.001)• Blood glucose monitoring frequency decreased
(4.9 to 4.5/day; P <.02) • Change in HbA1c associated with change in blood
glucose monitoring frequency (P <.001)
Rausch JR, et al. Diabetes Care. 2012;35:1219-1224.
![Page 52: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/52.jpg)
Adherence to Insulin in Adults with Diabetes
• Internet survey of US adults (N = 502)• 57% reported skipping insulin injections
– 20% regularly skip insulin injections
• Risk factors for intentional insulin omission – Type 2 vs type 1 diabetes– Higher number of injections– Perceived injection burden
Interference with daily activities Pain Embarrassment
Peyrot M, et al. Diabetes Care. 2010;33:240-245.
![Page 53: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/53.jpg)
Global Attitudes of Patients and Physicians in Insulin Therapy
(GAPP) Study
• Multinational internet survey– 1250 physicians– 1530 patients age ≥18 (n = 180 with type 1 diabetes)
• Patients – Overall: 33.2% reported being nonadherent ≥1 day in
previous month (mean 3.3 days)– US: 41.9% reported being nonadherent
2nd highest level among 8 countries in study
• Physicians– 72.5% reported that some patients do not take insulin as
prescribed
Peyrot M, et al. Diabet Med. 2012;29:682-689.
![Page 54: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/54.jpg)
Most Common Reasons for Insulin Omission/Nonadherence
• Was too busy• Was traveling• Skipped meals• Stress or emotional problems• Embarrassment• Difficult to take it at the same time every day
Peyrot M, et al. Diabet Med. 2012;29:682-689.
![Page 55: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/55.jpg)
Conclusions
• People with T1DM require insulin on a daily basis for survival
• Intensive diabetes treatment can prevent the development and progression of microvascular complications in diabetes
• Because there is metabolic memory, intensive diabetes treatment should be initiated as early in the course of T1DM as is possible
![Page 56: Insulin Therapy and Other Management Issues in Type 1 Diabetes Mellitus Philip Raskin, MD Jaime A. Davidson, MD The University of Texas Southwestern Medical](https://reader036.vdocuments.mx/reader036/viewer/2022062321/56649dc55503460f94ab8cde/html5/thumbnails/56.jpg)
Thank you for your participation.
To earn CME/CE/CPE credit, please complete the posttest and evaluation. (Click the link to the left of the slide presentation.)
Your feedback is appreciated and will help
us to continue to provide you with clinically relevant
educational activities that meet your specific needs.